Learn More
InBios International SCoV-2 Ag Detect™ Rapid Test

Description
- Point of Care: CLIA Waived test can be performed in a variety of settings, from physician offices to school health clinics, with symptomatic individuals. Do not use for individuals who have no symptoms or have had symptoms longer than 4 days
- Sequence analysis performed at InBios suggests test will detect variants currently in circulation, including KP.3.1.1
- Identifies acute infection in symptomatic patients: PPA (Relative Sensitivity): 84.2%, NPA (Relative Specificity): 99.8%
- Unique patent pending design – no mixing step
- Quick visual results – no instrumentation needed
- 50 test pack, includes positive and negative controls
- Room temperature storage
- 100% manufactured in the USA
Specifications
Specifications
| Certifications/Compliance | FDA 510(k) Cleared |
| Content And Storage | 20 to 30°C |
| CPT Code | 87811 |
| CE Marker | CE-IVD |
| Clia Complexity | Waived |
| Detectable Analytes | SARS-CoV-2 |
| Detection Method | Visual |
| DoA Calibrators | No |
| Type | rapid test |
| Disposable | Single-use |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.